Early-Stage Nodular Lymphocyte-Predominant Hodgkin Lymphoma: The Impact of Radiation Therapy on Overall Survival

Background: Few studies have examined whether the use of adjuvant treatment impacts survival for early stage high-grade salivary tumors. Methods: A retrospective review of the SEER database between 1973 and 2012 was performed. Patients with high-grade major salivary gland tumors including salivary duct carcinoma, carcinoma ex-pleomorphic adenoma, high-grade mucoepidermoid carcinoma, or adenocarcinoma, NOS were identified. Only stage I-II tumors were included. The impact of radiation status on observed and relative survival was examined. Results: Five hundred seventy-four patients with high-grade, early stage salivary tumors met inclusion criteria. Sixty-seven percent of patients received radiation therapy. There was no difference in observed or relative survival based on having received radiation. Conclusions: Adjuvant radiation is indicated for advanced stage tumors or early stage tumors with adverse features. For early stage tumors without adverse features, there was no survival benefit from radiation therapy. Adjuvant radiation should be decided on a case-by-case basis for these patients.

Download Full-text

Impact of Cardiac Radiation Dosimetry on Overall Survival in Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2018.06.239 ◽

2018 ◽

Vol 102 (3) ◽

pp. S92

Author(s):

S. Chan ◽

N. Shaverdian ◽

D. Ruan ◽

M. Cao ◽

G. Raghavan ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Radiation Therapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Radiation Dosimetry ◽

Stereotactic Body Radiation Therapy ◽

Early Stage ◽

Small Cell ◽

Small Cell Lung

Download Full-text

The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: The SORAMIC trial palliative cohort

Annals of Oncology ◽

10.1093/annonc/mdy149.028 ◽

2018 ◽

Vol 29 ◽

pp. v110 ◽

Cited By ~ 1

Author(s):

J. Ricke ◽

B. Sangro ◽

H. Amthauer ◽

I. Bargellini ◽

P. Bartenstein ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Overall Survival ◽

Radiation Therapy ◽

Advanced Hepatocellular Carcinoma ◽

Selective Internal Radiation Therapy ◽

Internal Radiation ◽

Selective Internal Radiation ◽

Internal Radiation Therapy ◽

The Impact

Download Full-text

Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy

Hematology ◽

10.1182/asheducation.v2012.1.313.3797303 ◽

2012 ◽

Vol 2012 (1) ◽

pp. 313-321 ◽

Cited By ~ 2

Author(s):

Ralph M. Meyer ◽

Richard T. Hoppe

Keyword(s):

Clinical Trials ◽

Radiation Therapy ◽

Hodgkin Lymphoma ◽

Early Stage ◽

Trial Protocol ◽

Radiation Oncologist ◽

Limited Stage ◽

Considerable Debate

Abstract The results of recent clinical trials for the management of limited-stage Hodgkin lymphoma have led to considerable debate, especially regarding the role of radiation therapy. This review highlights those recent trials and provides perspectives regarding their interpretation from a radiation oncologist and a hematologist. The trial protocol is available at http://www.nejm.org/doi/suppl/10.1056/NEJMoa1111961/suppl_file/nejmoa1111961_protocol.pdf.

Download Full-text

Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2006.07.5937 ◽

2006 ◽

Vol 24 (30) ◽

pp. 4833-4839 ◽

Cited By ~ 940

Author(s):

Robert Timmerman ◽

Ronald McGarry ◽

Constantin Yiannoutsos ◽

Lech Papiez ◽

Kathy Tudor ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Radiation Therapy ◽

Phase Ii ◽

Local Control ◽

Stereotactic Body Radiation Therapy ◽

Early Stage ◽

Stage I ◽

Severe Toxicity ◽

Stereotactic Body Radiation

PurposeSurgical resection is standard therapy in stage I non–small-cell lung cancer (NSCLC); however, many patients are inoperable due to comorbid diseases. Building on a previously reported phase I trial, we carried out a prospective phase II trial using stereotactic body radiation therapy (SBRT) in this population.Patients and MethodsEligible patients included clinically staged T1 or T2 (≤ 7 cm), N0, M0, biopsy-confirmed NSCLC. All patients had comorbid medical problems that precluded lobectomy. SBRT treatment dose was 60 to 66 Gy total in three fractions during 1 to 2 weeks.ResultsAll 70 patients enrolled completed therapy as planned and median follow-up was 17.5 months. The 3-month major response rate was 60%. Kaplan-Meier local control at 2 years was 95%. Altogether, 28 patients have died as a result of cancer (n = 5), treatment (n = 6), or comorbid illnesses (n = 17). Median overall survival was 32.6 months and 2-year overall survival was 54.7%. Grade 3 to 5 toxicity occurred in a total of 14 patients. Among patients experiencing toxicity, the median time to observation was 10.5 months. Patients treated for tumors in the peripheral lung had 2-year freedom from severe toxicity of 83% compared with only 54% for patients with central tumors.ConclusionHigh rates of local control are achieved with this SBRT regimen in medically inoperable patients with stage I NSCLC. Both local recurrence and toxicity occur late after this treatment. This regimen should not be used for patients with tumors near the central airways due to excessive toxicity.

Download Full-text